{
    "id": "5e48b1ddd14c9f295d000012",
    "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "Here's my step-by-step analysis: **Step 1: Understand the question** The question asks whether natalizumab improves the disease course of secondary progressive multiple sclerosis (SPMS). **Step 2: Review relevant documents** I reviewed documents [0], [1], [2], [3], [10], [13], [16], [21], and [25] related to natalizumab and multiple sclerosis. **Step 3: Identify key points** From document [3], natalizumab is a humanized monoclonal antibody that prevents lymphocytes from binding to endothelial cells, thereby preventing their migration into the central nervous system (CNS). This suggests that natalizumab may slow down the progression of multiple sclerosis. From document [10], natalizumab has shown therapeutic benefit in placebo-controlled trials for relapsing-remitting multiple sclerosis (RRMS), with a 68% reduction in relapses and 80% reduction in new or enlarging T2 cerebral lesions. From document [13], natalizumab is recommended for patients with SPMS, especially those with highly active disease or moderate impairment (EDSS >2.5). **Step 4: Analyze the data** While there is limited data on natalizumab's effect on SPMS specifically, the available information suggests that natalizumab may slow down the progression of MS, including SPMS. **Step 5: Draw a conclusion** Based on the available data, it is likely that natalizumab improves the disease course of secondary progressive multiple sclerosis. **Answer** {\"step_by_step_thinking\": \"Based on the available data, natalizumab may improve the disease course of secondary progressive multiple sclerosis, although more research is needed to confirm this effect.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_31013",
            "title": "InternalMed_Harrison",
            "content": "Multiple Sclerosis and Other Demyelinating DiseasesChapter 458Secondary progressive MS With relapses Without relapses Consider 1. IFN-\u02dc1a, or2. IFN-\u02dc1b Intolerant or poor response 1. Mitoxantrone 2. Azathioprine 3. Methotrexate 4. Pulse cyclophosphamide 5. IVIg 6. Pulse methylprednisolone No proven treatment Primary progressive MS Symptomatic therapy Progressive MS Consider Rx with one of the following: FIGURE 458-4 Therapeutic decision-making for multiple sclerosis (MS). *Can include trials of different preparations of interferon \u03b2 (IFN-\u03b2, particularly advancing from once-weekly (Avonex) to a more frequent (e.g., Rebif, Betaseron/Extavia) dosing regimen. Options also include use of natalizumab in JC virus\u2013positive patients. MRI, magnetic resonance imaging."
        },
        {
            "id": "Immunology_Janeway_4074",
            "title": "Immunology_Janeway",
            "content": "Fig. 16.10 Treatment with an anti-\u03b14 integrin humanized monoclonal antibody reduces relapses in multiple sclerosis. Left panel: interaction between \u03b14:\u03b21 integrin (VLA-4) on lymphocytes and macrophages and VCAM-1 expressed on endothelial cells permits the adhesion of these cells to brain endothelium. This facilitates the migration of these cells into the plaques of inflammation in multiple sclerosis. Center panel: the monoclonal antibody natalizumab (blue) binds to the \u03b14 chain of the integrin and blocks adhesive interactions between lymphocytes and monocytes and VCAM-1 on endothelial cells, thus preventing the cells from entering the tissue and exacerbating the inflammation. The future of this treatment is unclear because of the development of a rare infection as a side-effect (see the text). Right panel: the number of new lesions detected on magnetic resonance imaging (MRI) of the brain is greatly reduced in patients treated with natalizumab compared with a placebo. Data from"
        },
        {
            "id": "InternalMed_Harrison_31016",
            "title": "InternalMed_Harrison",
            "content": "moDerAte or SeVere initiAl courSe In highly active disease or moderate impairment (EDSS >2.5), either a highly effective oral agent (DMF or fingolimod) or, if the patient is JC virus antibody seronegative, infusion therapy with natalizumab is recommended. Regardless of which agent is chosen first, treatment should probably be changed in patients who continue to have relapses, progressive neurologic impairment or, arguably, ongoing evidence of subclinical MRI activity (Fig. 458-4)."
        },
        {
            "id": "InternalMed_Harrison_30993",
            "title": "InternalMed_Harrison",
            "content": "Natalizumab Natalizumab is a humanized monoclonal antibody directed against the \u03b14 subunit of \u03b14\u03b21 integrin, a cellular adhesion molecule expressed on the surface of lymphocytes. It prevents lymphocytes from binding to endothelial cells, thereby preventing lymphocytes from penetrating the BBB and entering the CNS. Natalizumab is highly effective in reducing the attack rate and significantly improves all measures of disease severity in MS (both clinical and MRI). Moreover, it is well-tolerated, and the dosing schedule of monthly intravenous infusions makes it very convenient for patients. However, progressive multifocal leukoencephalopathy (PML), a life-threatening condition resulting from infection by the John Cunningham (JC) virus, has occurred in approximately 0.3% of patients treated with natalizumab. The incidence of PML is very low in the first year of treatment but then rises by the second year to reach a level of about 2 cases per 1000 patients per year. Nevertheless, the"
        },
        {
            "id": "Immunology_Janeway_4068",
            "title": "Immunology_Janeway",
            "content": "and into the gut wall in Crohn\u2019s disease. However, blockade of \u03b14:\u03b21 integrin is not specific and, like anti-TNF therapy, could lead to reduced defense against infection. Rarely patients treated with natalizumab have developed progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus. This led to the temporary withdrawal of natalizumab from the market in 2005, but in June 2006 it was again allowed to be prescribed for multiple sclerosis and for Crohn\u2019s disease."
        },
        {
            "id": "InternalMed_Harrison_30995",
            "title": "InternalMed_Harrison",
            "content": "have a particularly aggressive disease course. Head-to-head data show that natalizumab is superior to low-dose (weekly) IFN-\u03b2-1a in RRMS. However, its relative efficacy compared to other agents has not been established conclusively."
        },
        {
            "id": "InternalMed_Harrison_31012",
            "title": "InternalMed_Harrison",
            "content": "milD initiAl courSe In the case of recent onset, normal exam or minimal impairment (EDSS \u22642.5 or less), or low disease activity, either an injectable (IFN-\u03b2 or glatiramer acetate) or an oral (DMF, Continue therapy Good response Intolerant or poor response Continue periodic clinical/ MRI assessments No change Successive trials of alternatives* Identify and treat any underlying infection or trauma Exacerbation Pseudoexacerbation Initial course Mild Moderate or severe Acute neurologic change Stable Relapsing-Remitting MS Functional impairment No functional impairment ?Low attack frequency or single attack ?Normal neurologic exam ?Low disease burden by MRI No Yes Repeat clinical exam and MRI in 6 months Clinical or MRI change Options: 1. Injectable (GA or IFB-\u02dc) 2. Oral (DMF, fingolimod, or (teriflunomide) 3. Natalizumab (if JCV-negative) Options: 1. Oral (DMF, fingolimod, or (teriflunomide) 2. Natalizumab (if JCV-negative) Methylprednisolone/ prednisone Symptomatic therapy"
        },
        {
            "id": "InternalMed_Harrison_24662",
            "title": "InternalMed_Harrison",
            "content": "It is important to realize the potential risks of these immunosuppressive monoclonal antibodies. Natalizumab is a humanized IgG antibody against an a4 integrin that inhibits leukocyte migration into tissues and has been approved for treatment of multiple sclerosis in the United States. Both it and anti-CD20 (rituximab) have been associated with the onset of progressive multifocal leukoencephalopathy (PML)\u2014a serious and usually fatal CNS infection caused by JC polyomavirus. Efalizumab, a humanized IgG monoclonal antibody previously approved for treatment of plaque psoriasis, has now been taken off the market due to reactivation of JC virus leading to fatal PML. Thus, use of any currently approved immunosuppressant immunotherapies should be undertaken with caution and with careful monitoring of patients according to FDA guidelines."
        },
        {
            "id": "Neurology_Adams_7459",
            "title": "Neurology_Adams",
            "content": "Pittock SJ, Mayr WT, McClelland RL, et al: Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 62:601, 2004. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63:964, 2006. Polman CH, O\u2019Connor PW, Havardova E, et al: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899, 2006. Polman CH, Reingold SC, Banwell B, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292, 2011. Poser CM: Exacerbations, activity and progression in multiple sclerosis. Arch Neurol 37:471, 1980. Poser CM, Goutieres F, Carpentier M: Schilder\u2019s myelinoclastic diffuse sclerosis. Pediatrics 77:107, 1986. Poskanzer DC, Schapira K, Miller H: Multiple sclerosis and poliomyelitis. Lancet 2:917, 1963."
        },
        {
            "id": "Neurology_Adams_7466",
            "title": "Neurology_Adams",
            "content": "Weinshenker BG, Rice GP, Noseworthy JH, et al: The natural history of multiple sclerosis: A geographically based study: 2. Predictive value of the early clinical course. Brain 112:1419, 1989. Wenning W, Haghikia A, Laubenberger J, et al: Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075, 2009. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177, 2015. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 6:805, 2007. Wingerchuk DM, Lennon VA, Pittock SJ, et al: Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485, 2006. Zivadinov R, Rudick RA, De Masi R, et al: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239, 2001."
        },
        {
            "id": "Pharmacology_Katzung_6186",
            "title": "Pharmacology_Katzung",
            "content": "release of IL-1\u03b2, causing autoimmune inflammation resulting in fever, urticarial-like rash, arthralgia, myalgia, fatigue, and conjunctivitis. Natalizumab is a humanized IgG4 monoclonal antibody that binds to the \u03b14-subunit of \u03b14\u03b21 and \u03b14\u03b27 integrins expressed on the surfaces of all leukocytes except neutrophils. It inhibits the \u03b14-mediated adhesion of leukocytes to their cognate receptor. It is indicated for patients with multiple sclerosis and Crohn\u2019s disease who have not tolerated or had inadequate responses to conventional treatments. Natalizumab should not be used with any of the anti-TNF-\u03b1 drugs listed above. Natalizumab increases risk of progressive multifocal leukoencephalopathy."
        },
        {
            "id": "InternalMed_Harrison_22983",
            "title": "InternalMed_Harrison",
            "content": "One case of progressive multifocal leukoencephalopathy (PML) after eight infusions of natalizumab was observed among 1043 patients in the clinical trials for CD, and two patients developed PML in the multiple sclerosis (MS) trials after a median of 120 weeks. There were 410 postmarketing cases of PML, 408 in MS and 2 in CD. The most important risk factor for development of PML is exposure to the John Cunningham (JC) polyomavirus, seen in 50\u201355% of the adult population. The other two risk factors for development of PML are longer duration of treatment, especially beyond 2 years, and prior treatment with an immunosuppressant medication. Patients with all three risk factors have an estimated risk of 11:1000."
        },
        {
            "id": "Immunology_Janeway_4253",
            "title": "Immunology_Janeway",
            "content": "Hallegua, D.S., and Weisman, M.H.: Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann. Rheum. Dis. 2002, 61:960\u2013967. Karanikolas, G., Charalambopoulos, D., Vaiopoulos, G., Andrianakos, A., Rapti, A., Karras, D., Kaskani, E., and Sfikakis, P.P.: Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology 2008, 47:1384\u20131388. Mackay, C.R.: New avenues for anti-inflammatory therapy. Nat. Med. 2002, 8:117\u2013118. 16-9 Biologic agents can block cell migration to sites of inflammation and reduce immune responses. Boster, A.L., Nicholas, J.A., Topalli, I., Kisanuki, Y.Y., Pei, W., Morgan-Followell, B., Kirsch, C.F., Racke, M.K., and Pitt, D.: Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013, 70:398\u2013402."
        },
        {
            "id": "Neurology_Adams_7453",
            "title": "Neurology_Adams",
            "content": "Kurtzke JF, Hyllested K: Multiple sclerosis in the Faroe Islands: II. Clinical update, transmission, and the nature of MS. Neurology 36:307, 1986. Lennon VA, Wingerchuk DM, Kryzer TJ, et al: A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 364:2106, 2004. Lessell S: Corticosteroid treatment of acute optic neuritis. N Engl J Med 326:634, 1992. Lightman S, McDonald WI, Bird AC, et al: Retinal venous sheathing in optic neuritis. Brain 110:405, 1987. Lind\u00e5 H, von Heijne A, Major EO, et al: Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361:1081, 2009. Lublin FD, Cofield SS, Cutter GR, et al: Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 73:327, 2013. Lucchinetti CF, Br\u00fcck W, Parisi J, et al: Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47:707, 2000."
        },
        {
            "id": "Neurology_Adams_7461",
            "title": "Neurology_Adams",
            "content": "Renoux C, Vukusic S, Mikaeloff Y, et al: Natural history of multiple sclerosis with childhood onset. N Engl J Med 356:2603, 2007. Rizzo JF III, Lessell S: Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study. Neurology 38:185, 1988. Rodriguez M, Karnes WE, Bartelson JD, Pineda AA: Plasmapheresis in acute episodes of fulminant inflammatory demyelination. Neurology 43:1100, 1993. Ropper AH, Poskanzer DC: The prognosis of acute and subacute transverse myelitis based on early signs and symptoms. Ann Neurol 4:51, 1978. Rudick RA, Stuart WH, Calabrese PA, et al: Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911, 2006. Sadovnick AD, Baird PA, Ward RH: Multiple sclerosis: Updated risks for relatives. Am J Med Genet 29:533, 1988. Sadovnick AD, Ebers GC, Dyment DA, et al: Evidence for a genetic basis for multiple sclerosis. Lancet 347:1728, 1996."
        },
        {
            "id": "InternalMed_Harrison_11070",
            "title": "InternalMed_Harrison",
            "content": "Almost all patients have an underlying immunosuppressive disorder or are receiving immunomodulatory therapy. In recent series, the most common associated conditions were AIDS (80%), hematologic malignancies (13%), transplant recipients (5%), and chronic inflammatory diseases (2%). It has been estimated that up to 5% of AIDS patients will develop PML. There have been over 400 reported cases of PML occurring in patients being treated for multiple sclerosis and inflammatory bowel disease with natalizumab, a humanized monoclonal antibody that inhibits lymphocyte trafficking into CNS and bowel mucosa by binding to \u03b14 integrins. Overall risk in these patients has been estimated at ~3.4 PML cases per 1000 treated patients, but the risk depends on a variety of factors including anti-JCV antibody serostatus, prior immunosuppressive therapy use, and duration of natalizumab therapy. Patients who lack detectable JCV antibody have a risk of developing PML of <0.1 case/1000 patients, whereas those"
        },
        {
            "id": "Neurology_Adams_7366",
            "title": "Neurology_Adams",
            "content": "Monoclonal antibodies One approach to treatment has been the use of monoclonal antibodies to various components of the inflammatory response. Natalizumab is directed against alpha-integrin in order to block lymphocyte and monocyte adhesion to endothelial cells and their migration through the vessel wall. It has been used in rheumatoid arthritis and fistulizing Crohn disease. In a study that ran for 6 months, Miller and colleagues (2003) were able to demonstrate a reduction in the number of relapses and a slowing of the accumulation of MRI lesions. A double-blind, placebo-controlled study of 942 patients with relapsing\u2013remitting MS (Polman et al, 2006; the AFFIRM study) showed a 68 percent reduction in relapses, an 80 percent reduction in new or enlarging T2 cerebral lesions and a 96 percent reduction in gadolinium-enhancing lesions on MRI after a year. This represents a twofold improvement in efficacy compared to what has been reported with interferon and glatiramer acetate. There was"
        },
        {
            "id": "Neurology_Adams_7447",
            "title": "Neurology_Adams",
            "content": "Gilbert JJ, Sadler M: Unsuspected multiple sclerosis. Arch Neurol 40:533, 1983. Gold R, Kappos L, Arnold DL, et al: Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N Engl J Med; 367:1098, 2012. Goodkin DE, Rudick RA, Medendorp V, et al: Low-dose oral methotrexate in chronic progressive multiple sclerosis. Neurology 47:1153, 1996. Hallett M, Lindsey JW, Adelstein BD, Riley PO: Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 35:1314, 1985. Halliday AM, McDonald WI: Pathophysiology of demyelinating disease. Br Med Bull 33:21, 1977. Hartung HP, Gonsette R, Konig H, et al: Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind randomised, multicentre trial. Lancet 360:2018, 2002."
        },
        {
            "id": "InternalMed_Harrison_30994",
            "title": "InternalMed_Harrison",
            "content": "with natalizumab. The incidence of PML is very low in the first year of treatment but then rises by the second year to reach a level of about 2 cases per 1000 patients per year. Nevertheless, the measurement of antibodies against the JC virus in the serum can be used to stratify this risk. Thus, in patients who do not have these antibodies, the risk of PML is either minimal or nonexistent (as long as they remain JC antibody free). Conversely, in patients who have these antibodies (especially those who have them in high titer), the risk may be as high as 0.6% or greater. The risk is also high in patients who have previously received immunosuppressive therapy. Natalizumab is currently recommended only for JC antibody\u2013negative patients, unless they have failed alternative therapies or if they have a particularly aggressive disease course. Head-to-head data show that natalizumab is superior to low-dose (weekly) IFN-\u03b2-1a in RRMS. However, its relative efficacy compared to other agents has"
        },
        {
            "id": "Neurology_Adams_7451",
            "title": "Neurology_Adams",
            "content": "Kappos L, Antel J, Comi G, et al: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124, 2006. Kappos L, Li D, Calabresi PA, et al: Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled multicentre trial. Lancet 378:1779, 2011. Kappos L, Radue EW, O\u2019Connor P, et al; FREEDOMS Study Group: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387, 2010. Katz J, Ropper AH: Progressive necrotic myelopathy: Clinical course in 9 patients. Arch Neurol 57:355, 2000. Kepes JJ: Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis: A study of 31 patients. Ann Neurol 33:18, 1993. Kidd D, Burtan B, Plant GT, et al: Chronic relapsing inflammatory optic neuropathy. Brain 126:276, 2003."
        },
        {
            "id": "Neurology_Adams_7464",
            "title": "Neurology_Adams",
            "content": "Thygessen P: The Course of Disseminated Sclerosis: A Close-Up of 105 Attacks. Copenhagen, Rosenkilde and Bagger, 1953. Tippett DS, Fishman PS, Panitch HS: Relapsing transverse myelitis. Neurology 41:703, 1991. Tourtellotte WW, Booe IM: Multiple sclerosis: The blood-brain barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28(Suppl):76, 1978. Tradtrantip L, Zhang H, Saadoun S, et al: Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314, 2014. Tremlett H, Paty D, Devonshire V; Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172, 2006. van der Mei IA, Ponsonby AL, Dwyer T, et al: Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581, 2007. Vermersch F, Kappos L, Gold R, et al: Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697, 2011."
        },
        {
            "id": "Immunology_Janeway_4067",
            "title": "Immunology_Janeway",
            "content": "Effector lymphocytes expressing the integrin \u03b14:\u03b21 (VLA-4) bind to VCAM-1 on endothelium in the central nervous system, while those expressing integrin \u03b14:\u03b27 (lamina propria-associated molecule 1) bind to MAdCAM-1 on the endothelium in the gut. The humanized monoclonal antibody natalizumab is specific for the \u03b14 integrin subunit and binds both VLA-4 and \u03b14:\u03b27, preventing their interaction with their ligands (Fig. 16.10). This antibody has shown therapeutic benefit in placebo-controlled trials in patients with Crohn\u2019s disease or with multiple sclerosis. The early signs that this treatment could be successful illustrate the fact that disease depends on the continuing emigration of lymphocytes, monocytes, and macrophages from the circulation into the tissues of the brain in multiple sclerosis, and into the gut wall in Crohn\u2019s disease. However, blockade of \u03b14:\u03b21 integrin is not specific and, like anti-TNF therapy, could lead to reduced defense against infection. Rarely patients treated"
        },
        {
            "id": "Neurology_Adams_7448",
            "title": "Neurology_Adams",
            "content": "Hartung HP, Gonsette R, Konig H, et al: Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind randomised, multicentre trial. Lancet 360:2018, 2002. Hauser SL, Bresnan MJ, Reinherz EL, Weiner HL: Childhood multiple sclerosis: Clinical features and demonstration of changes in T-cell subsets with disease activity. Ann Neurol 11:463, 1982. Hauser SL, Dawson DM, Lehrich JR: Intensive immune suppression in progressive multiple sclerosis: A randomized three arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 308:173, 1983. Hauser SA, Waubant E, Arnold DL, et al: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676, 2008. Hely MA, McManis PG, Doran TJ, et al: Acute optic neuritis: A prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry 49:1125, 1986."
        },
        {
            "id": "Immunology_Janeway_4254",
            "title": "Immunology_Janeway",
            "content": "Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G., and Nath, A.: Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438\u2013446. Cyster, J.G.: Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 2005, 23:127\u2013159. Idzko, M., Hammad, H., van Nimwegen, M., Kool, M., Muller, T., Soullie, T., Willart, M.A., Hijdra, D., Hoogsteden, H.C., and Lambrecht, B.N.: Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J. Clin. Invest. 2006, 116:2935\u20132944. Kappos, L., Radue, E.W., O\u2019Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387\u2013401."
        },
        {
            "id": "Neurology_Adams_7360",
            "title": "Neurology_Adams",
            "content": "with the secondarily progressive type of MS; progression of the disease was delayed for 9 to 12 months in a study period of 2 to 3 years. The treatment of relapsing\u2013remitting MS with IFN-\u03b2-1a in a once weekly intramuscular regimen is similarly effective."
        },
        {
            "id": "Neurology_Adams_7371",
            "title": "Neurology_Adams",
            "content": "Rituximab, a murine B-cell-depleting monoclonal antibody that targets CD20 lymphocytes, has been tested in several trials and found to be effective in reducing relapses and the accumulation of MRI lesions of relapsing\u2013remitting cases over 4 years, but long-term safety is still being established (Hauser et al, 2008). A similar, fully humanized anti-CD20 drug, ocrelizumab, has been introduced and has similar effects to rituximab (Kappos et al, 2011). In addition to its indication for relapsing remitting MS, it has tentatively been shown to have some effect on primary progressive MS. Appropriate use in patients should be balanced by consideration of its risks, which include opportunistic infection as well as malignancy."
        },
        {
            "id": "Neurology_Adams_7442",
            "title": "Neurology_Adams",
            "content": "Bobholz JA, Rao SM: Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 16:283, 2003. Bot JC, Barkhof F, Polman CH, et al: Spinal cord abnormalities in recently diagnosed MS patients. Added value of spinal MRI examination. Neurology 62:226, 2004. British and Dutch Multiple Sclerosis Azathioprine Trial Group: Double masked trial of azathioprine in multiple sclerosis. Lancet ii:179, 1988. CAMMS223 Trial Investigators et al: A randomized, rater-blinded, trial of alemtuzumab versus interferon beta-1a in early, relapsing remitting multiple sclerosis. N Engl J Med 359:1786, 2008. CHAMPS Study Group: Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463, 2001. Cohen JA, Barkhof F, Comi G, et al; TRANSFORMS Study Group: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402, 2010."
        },
        {
            "id": "Immunology_Janeway_4075",
            "title": "Immunology_Janeway",
            "content": "the text). Right panel: the number of new lesions detected on magnetic resonance imaging (MRI) of the brain is greatly reduced in patients treated with natalizumab compared with a placebo. Data from Miller, D.H., et al.:"
        },
        {
            "id": "Immunology_Janeway_4057",
            "title": "Immunology_Janeway",
            "content": "Alemtuzumab, discussed above for its use in treating leukemia and in transplant rejection, has shown some beneficial effect in studies of small numbers of patients with multiple sclerosis. However, immediately after its infusion, most multiple sclerosis patients suffered a frightening, although fortunately brief, flare-up of their illness, illustrating another potential complication of antibody therapy. Alemtuzumab was acting as intended, killing cells by complementand Fc-dependent mechanisms. However, it also stimulated the release of cytokines, including TNF-\u03b1, interferon (IFN)-\u03b3, and IL-6, which transiently block nerve conduction in nerve fibers previously affected by demyelination. This caused the transient but dramatic exacerbation of symptoms. Nevertheless, alemtuzumab may be useful at early stages of the disease, when the inflammatory response is maximal, but this has yet to be determined."
        },
        {
            "id": "Neurology_Adams_10014",
            "title": "Neurology_Adams",
            "content": "Because of slow evolution, the clinical picture can easily be confused with that of progressive spastic paraplegia of the heredofamilial variety, sporadic motor neuron disease, or the chronic phase of multiple sclerosis. There are also similarities with the AIDS myelopathy described earlier, but the other features of HIV infection are absent. A single intravenous infusion of the anti-CCR4 T-cell antibody, mogamulizumab, has been shown in preliminary studies to reduce viral load and improve spasticity and motor function (Sato et al). Myelitis Secondary to Bacterial, Fungal, Parasitic, and Granulomatous Diseases (See Also Chap. 31)"
        },
        {
            "id": "Neurology_Adams_7465",
            "title": "Neurology_Adams",
            "content": "Tasmania, Australia. J Neurol 254:581, 2007. Vermersch F, Kappos L, Gold R, et al: Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697, 2011. Vrethem M, Mattsson E, Hebelka H, et al: Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 9:239, 2003. Waksman BH, Adams RD: Studies of the effect of the Schwartzman reaction on the lesions of experimental allergic encephalomyelitis. Am J Pathol 33:131, 1957. Weinshenker BG, O\u2019Brien PC, Petterson TM, et al: A randomized trial of plasma exchange in acute central nervous system demyelinating inflammatory disease. Ann Neurol 46:878, 1999. Weinshenker BG, Rice GP, Noseworthy JH, et al: The natural history of multiple sclerosis: A geographically based study: 2. Predictive value of the early clinical course. Brain 112:1419, 1989."
        },
        {
            "id": "Neurology_Adams_7441",
            "title": "Neurology_Adams",
            "content": "Beck RW, Cleary PA, Anderson MM Jr, et al: A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 326:581, 1992. Beck RW, Trobe JD, Moke PS, et al: Highand low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol 121:944, 2003. Beebe GW, Kurtzke JF, Kurland LT, et al: Studies on the natural history of multiple sclerosis: 3. Epidemiologic analyses of the Army experience in World War II. Neurology 17:1, 1967. Birk K, Rudick R: Pregnancy and multiple sclerosis. Arch Neurol 43:719, 1986. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870, 2012. Bobholz JA, Rao SM: Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 16:283, 2003."
        }
    ],
    "scores": [
        0.036399490351696234,
        0.03494872625888669,
        0.03334343903690908,
        0.03255470164688516,
        0.032429511650714435,
        0.03232583145383637,
        0.03217465335429252,
        0.0316839859103521,
        0.03125474045864694,
        0.03122628193577626,
        0.031012323833064535,
        0.030352519189011766,
        0.030043693731075235,
        0.029581986648323292,
        0.029074919771576155,
        0.02903885640713328,
        0.026955250760175915,
        0.026240114609098565,
        0.02588451555357284,
        0.025033105603438396,
        0.02398938522777532,
        0.023904526845703315,
        0.023823196218602287,
        0.023653405588071878,
        0.02345700637828159,
        0.0232306846730174,
        0.023193677739132286,
        0.023037940008218055,
        0.022833442928379636,
        0.022764916243177113,
        0.02237287049682938,
        0.022276768991147652
    ]
}